Poiano (IT)
{name}
{subtitle}
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)
city
~4 mi. (Verona, Italy, +226 more cities)
facility
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma-Oncology Unit ( Site 0465)
condition
Prostate Adenocarcinoma
drug
enzalutamide, +1 more drug
drug type
hormone therapy, +1 more type
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
city
~4 mi. (Verona, Italy, +93 more cities)
facility
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento ( Site 0598)
condition
Bladder Carcinoma, +1 more condition
drug
cisplatin, +4 more drugs
drug type
chemotherapy, +3 more types
A Study of RO7121661 and RO7247669 Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus
city
~4 mi. (Verona, Italy, +60 more cities)
facility
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Roma
condition
Esophageal Squamous Cell Carcinoma
drug
RO7121661, +1 more drug
drug type
immunotherapy
Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)
city
~4 mi. (Verona, Italy, +26 more cities)
facility
Novartis Investigative Site
condition
Pancreatic Adenocarcinoma
drug
gemcitabine, +3 more drugs
drug type
chemotherapy, +1 more type
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
city
~8 mi. (Negrar, Italy, +262 more cities)
facility
Ospedale Sacro Cuore Don Calabria
biomarker
ER Positive, +1 more biomarker
condition
Breast Adenocarcinoma
drug
giredestrant, +2 more drugs
drug type
hormone therapy, +1 more type
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Either Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
city
~8 mi. (Negrar, Italy, +52 more cities)
facility
GSK Investigational Site
biomarker
BRCA1 Loss, +8 more biomarkers
condition
Breast Carcinoma
drug
niraparib
drug type
targeted therapy